RETRACTED: Cerebrospinal fluid of Alzheimer patients promotes β-amyloid fibril formation in vitro
Authors:
- Moeko NoguchiMNMoeko Noguchi
- Yasuko MatsumotoYMYasuko Matsumoto
- Daisuke YanaseDYDaisuke Yanase
- Kazuo IwasaKIKazuo Iwasa
- Hironobu NaikiHNHironobu Naiki
- Masahito YamadaMYMasahito Yamada
- 1 November 2005
- journal article
- retracted article
- Published by Elsevier in Neurobiology of Disease
- Vol. 20 (2) , 233-240
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of PathogenesisScience, 2003
- Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseasesNature, 2002
- Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's DiseaseBiochemistry, 1999
- α2‐Macroglobulin Attenuates β‐Amyloid Peptide 1–40 Fibril Formation and Associated Neurotoxicity of Cultured Fetal Rat Cortical NeuronsJournal of Neurochemistry, 1998
- Concentration-Dependent Inhibitory Effects of Apolipoprotein E on Alzheimer's β-Amyloid Fibril Formation in VitroBiochemistry, 1997
- Cerebrospinal fluid apolipoprotein E is reduced in Alzheimerʼs diseaseNeuroReport, 1994
- Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease.Proceedings of the National Academy of Sciences, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- Determination of proteins by using the color reaction with pyrocatechol violet-molybdenum(VI) complex.Chemical and Pharmaceutical Bulletin, 1984
- A New Clinical Scale for the Staging of DementiaThe British Journal of Psychiatry, 1982